ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
2,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
3,1,Supraventricular tachycardia,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
4,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
5,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
6,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
6,2,Headache,Headaches NEC,Headaches,Nerv,N
6,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
7,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
8,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
8,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
